European Journal of Cardio-Thoracic Surgery, Vol 10, 456-460, Copyright © 1996 by European Association for Cardio-thoracic Surgery
Coronary autoregulation protects against harmful effects of commonly used cardioplegia delivery pressure
O Irtun and DG Sorlie
Department of Surgery, University of Tromso, Regionsykehuset i Tromso, Norway.
OBJECTIVE: Hearts or parts of hearts are often ischemic prior to infusion
of the cardioplegic solution and have a more or less dilated coronary bed.
We made an investigation whether coronary dilation just prior to induction
of cardiac arrest by aortic clamping and infusion of crystalloid
cardioplegic solution would influence cardioprotection. METHODS: Isolated
buffer-perfused rat hearts (100 cm H2O pressure (= 73.5 mmHg), 37 degrees
C) were used. After a stabilization period the perfusion of 8 rats (group
1) was stopped and the hearts arrested with 5 ml CS (100 cm H2O, 12 degrees
C). Equal amounts of cardioplegic solution were then delivered every 20
minutes for the entire 3 1/2 hour hypothermic ischemic period. Following
ischemia the hearts were reperfused for 60 minutes. In group 2 (n = 8) 1 ml
10(-2) mmol Papaverine was given into the aortic root just prior to the
first cardioplegic solution infusion in order to induce coronary
vasodilation. The procedure was identical in the two groups during ischemia
and reperfusion. RESULTS: During the ischemic period coronary resistance
increased in group 2. During reperfusion group 2 had lower coronary flow (P
= 0.001), left ventricle developed pressure (P = 0.002) and a higher
creatine kinase release (P = 0.003) than group 1 hearts. Group 2 also had a
lower adenosine-triphosphate (6.51 +/- 0.40 mumol.g-1 and 14.03 +/- 0.59
mumol.g-1, respectively, P = 0.011), creatine phosphate (24.70 +/- 1.02
mumol.g-1 and 36.50 +/- 1.31 mumol.g- 1, respectively, P = 0.020) and a
larger fall in dry/wet-weight ratio (1.7 +/- 0.4 and 0.8 +/- 0.5,
respectively, P = 0.043). CONCLUSIONS: Vasodilation (i.e. ischemia) just
prior to infusion of crystalloid cardioplegic solution may impair
myocardial protection even when the cardioplegic solution is delivered at a
relatively low and presumably safe pressure.